News | July 14, 2011

Boston Scientific Completes Trial Enrollment for Adapt Monorail Carotid Stent

July 14, 2011 — Boston Scientific Corporation has completed patient enrollment in the ASTI post-market clinical follow-up study evaluating its Adapt monorail carotid stent system in combination with its FilterWire EZ embolic protection system for treatment of carotid artery disease in patients at high risk for carotid surgery.

The trial began in 2010 and has reached its enrollment goal of 100 patients at 11 sites in Europe. Principal investigator of the study is Marc Bosiers, M.D., head of the department of vascular surgery, A.Z. Sint-Blasius Hospital in Dendermonde, Belgium.  

The stent features thin struts and an innovative design engineered for flexibility in the carotid arteries. It incorporates a self-expanding, rolled nitinol sheet with patented dynamic tapering technology designed to conform to varying carotid anatomies. This second-generation carotid stent also provides excellent visibility and has a closed-cell geometry that facilitates consistent lesion coverage. It has been sold in Europe as well as other select countries since receiving CE mark in 2010.  

"The Adapt stent offers outstanding deliverability and scaffolding of the vessel wall, which are critical attributes for carotid stents," said Bosiers. "I look forward to seeing how the features of this new technology may be reflected in clinical outcomes from the ASTI study."

The study will examine rates of major adverse events, defined as any death, stroke or myocardial infarction at 30 days. Additionally, it will assess rates of late ipsilateral stroke, target lesion revascularization and in-stent restenosis.

In addition to the Adapt carotid stent, Boston Scientific markets the Carotid Wallstent Monorail Endoprosthesis. Both stents are mounted on monorail delivery systems and feature closed-cell designs intended to offer increased scaffolding of the vessel wall. Both stents are also designed to be used in conjunction with the FilterWire EZ embolic protection system, intended to capture plaque debris released during the stenting procedure. The Adapt carotid stent system is not available for sale in the United States.  

For more information: www.bostonscientific.com


Additional Content

News | Cardiovascular Clinical Studies

Nov. 1, 2026 – Abbott has announced the 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular ...

Home November 03, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 27, 2026 — Atrium Therapeutics, developer of RNA therapeutics targeted to the heart, has announced that the first ...

Home October 30, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 1, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the first patient enrollment in the IBE ...

Home October 01, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 31, 2026 — Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk ...

Home September 02, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2026 — A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had ...

Home August 21, 2026
Home
Subscribe Now